FPI-2053

DRUG2 trials

Conditions

Advanced Solid TumorEGFR Mutation-positive NSCLCGastric CancerHead and Neck Squamous Cell CarcinomaMetastatic Colorectal CarcinomaNon-small Cell Lung CancerPancreatic Ductal AdenocarcinomaRenal Cell Carcinoma

Phase 1

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

Active, not recruitingNCT06147037

AstraZenecaAdvanced Solid Tumor, Gastric Cancer, Head and Neck Squamous Cell Carcinoma +4

Start: 2024-07-31End: 2026-12-31Updated: 2026-07-07

Phase I Study of [111In]-FPI-2107 in EGFR Mutation-positive NSCLC

TerminatedNCT07500987

AstraZenecaEGFR Mutation-positive NSCLC

Start: 2026-02-27End: 2026-05-13Updated: 2026-09-11

FPI-2053

Sponsors

Conditions

Phase 1